INTAS Pharmaceuticals Limited, the 12th largest pharmaceutical company in India, has added Jamaica to an extensive network of branch offices and subsidiaries spanning USA, Canada, Europe, Central & Latin America, Africa, Asia-Pacific as well as CIS countries.
A leading vertically integrated global pharmaceutical formulation, development, manufacturing and marketing company headquartered in India, Intas is present in over 50 countries and its global strategy includes alliances with leading global pharmaceutical companies for development and distribution of products as well as direct product distribution.
Elizabeth Anderson, business manager for Intas in Jamaica, explained that the $350-million organisation "is one of the leading players in chronic therapy areas including diabetology, gastroenterology, gynaecology, infertility and respiratory care."
Headed by a strong pool of over 400 scientists and researchers, research and development activities are at the core of Intas which has led breakthrough innovations in a wide spectrum of areas and has filed over 50 formulation patents in the last three years alone.
Anderson noted that "Intas has made strategic investments in 10 manufacturing facilities in India, the United Kingdom and Mexico" while its subsidiary, Intas Biopharmaceuticals Limited "has made substantial investments in the development, manufacturing and marketing of products based on biotechnology in chronic therapy areas including oncology and nephrology."
Anderson said that Intas has a significant number of product approvals in regulated markets and healthy product development pipelines and is "now spreading its wings across the global pharma horizon with its turnover of approximately $20M in 2010 and aiming for generating five times growth to reach the $100M mark by 2013, from international markets."